SCHEMBL2230764

SCHEMBL2230764

Cc1ncccc1-c1cc2ccccn2c1C(=O)[C]=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.43
POLB P06746 1/20 0.39
KDM4E B2RXH2 3/20 0.39
RAB9A P51151 2/20 0.39
L3MBTL1 Q9Y468 6/20 0.38
HTT P42858 2/20 0.38
MAPT P10636 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
ATM Q13315 1/20 0.38
THRB P10828 1/20 0.38
MAPK1 P28482 4/20 0.37
MKNK1 Q9BUB5 1/20 0.36
MKNK2 Q9HBH9 1/20 0.36
BRD4 O60885 1/20 0.36
BRD2 P25440 1/20 0.36
BRD3 Q15059 1/20 0.36
BAZ2B Q9UIF8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1645071 0.83 SMN1; SMN2 (0.48) SMN1; SMN2POLBKDM4ERAB9AL3MBTL1
SCHEMBL3884093 0.69 SMN1; SMN2 (0.46) SMN1; SMN2KDM4ERAB9AL3MBTL1HTT
SCHEMBL3886862 0.65 SMN1; SMN2 (0.50) SMN1; SMN2POLBKDM4ERAB9AL3MBTL1
SCHEMBL31469002 0.64 MKNK1 (0.52) SMN1; SMN2KDM4EL3MBTL1HTTMAPT
SCHEMBL3421959 0.64 MKNK1 (0.52) SMN1; SMN2KDM4EL3MBTL1HTTMAPT
SCHEMBL7843650 0.64 MKNK1 (0.46) KDM4EMAPTMKNK1MKNK2BRD4
SCHEMBL3883352 0.63 BAZ2B (0.50) SMN1; SMN2POLBKDM4ERAB9AL3MBTL1
SCHEMBL30719725 0.63 KDM4E (0.53) KDM4EL3MBTL1MAPTCYP1A2ATM
SCHEMBL1645721 0.62 NPC1 (0.45) SMN1; SMN2POLBKDM4ERAB9AL3MBTL1
SCHEMBL4230190 0.62 KDM4E (0.68) SMN1; SMN2POLBKDM4ERAB9AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8604029-B2 2-[(2-substituted)-indolizin-3-yl]-2-oxo-acetamide derivatives as antifungal agents F2G LTD BRITISH BODY CORPORATE (GB) 2013-12-10 US disclosed
US-20110183969-A1 ANTIFUNGAL COMBINATION THERAPY F2G LTD (GB) 2011-07-28 US disclosed
US-20100056511-A1 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS F2G LTD. 2010-03-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110183969-A1 ANTIFUNGAL COMBINATION THERAPY IDO1, FOXM1, IPO5 SMN1; SMN2 3682/4885POLB 4825/4885KDM4E 2593/4885
US-20100056511-A1 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS NAT1, AGXT, CYP1A2 SMN1; SMN2 3079/4885POLB 4855/4885KDM4E 1543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.